{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:45:16Z","timestamp":1793724316968,"version":"4.6.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00415-025-13141-w","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T07:21:43Z","timestamp":1746861703000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Randomized controlled trials for multiple sclerosis: integrating pathology-driven outcomes to capture therapeutic efficacy"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Preziosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"issue":"9","key":"13141_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1177\/13524585231189671","volume":"29","author":"RA Marrie","year":"2023","unstructured":"Marrie RA et al (2023) Improving the efficiency of clinical trials in multiple sclerosis. Mult Scler 29(9):1136\u20131148","journal-title":"Mult Scler"},{"issue":"10","key":"13141_CR2","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M et al (2022) Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol 269(10):5382\u20135394","journal-title":"J Neurol"},{"issue":"1","key":"13141_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ana.26913","volume":"96","author":"M Calabrese","year":"2024","unstructured":"Calabrese M et al (2024) Determinants and biomarkers of progression independent of relapses in multiple sclerosis. Ann Neurol 96(1):1\u201320","journal-title":"Ann Neurol"},{"issue":"1","key":"13141_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann T et al (2023) Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol 22(1):78\u201388","journal-title":"Lancet Neurol"},{"issue":"11","key":"13141_CR5","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","volume":"80","author":"J Muller","year":"2023","unstructured":"Muller J et al (2023) Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review. JAMA Neurol 80(11):1232\u20131245","journal-title":"JAMA Neurol"},{"issue":"1","key":"13141_CR6","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1212\/WNL.0000000000011123","volume":"96","author":"MW Koch","year":"2021","unstructured":"Koch MW et al (2021) Reliability of outcome measures in clinical trials in secondary progressive multiple sclerosis. Neurology 96(1):e111\u2013e120","journal-title":"Neurology"},{"issue":"3","key":"13141_CR7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1474-4422(24)00027-9","volume":"23","author":"J Chataway","year":"2024","unstructured":"Chataway J et al (2024) Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges. Lancet Neurol 23(3):277\u2013301","journal-title":"Lancet Neurol"},{"issue":"9","key":"13141_CR8","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/14737175.2019.1555038","volume":"19","author":"MA Rocca","year":"2019","unstructured":"Rocca MA et al (2019) Application of advanced MRI techniques to monitor pharmacologic and rehabilitative treatment in multiple sclerosis: current status and future perspectives. Expert Rev Neurother 19(9):835\u2013866","journal-title":"Expert Rev Neurother"},{"issue":"12","key":"13141_CR9","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1177\/1352458513481009","volume":"19","author":"SM Steinvorth","year":"2013","unstructured":"Steinvorth SM et al (2013) Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression. Mult Scler 19(12):1580\u20131586","journal-title":"Mult Scler"},{"issue":"11","key":"13141_CR10","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1093\/brain\/awae251","volume":"147","author":"M Filippi","year":"2024","unstructured":"Filippi M et al (2024) The ageing central nervous system in multiple sclerosis: the imaging perspective. Brain 147(11):3665\u20133680","journal-title":"Brain"},{"issue":"9","key":"13141_CR11","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L et al (2020) Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol 77(9):1132\u20131140","journal-title":"JAMA Neurol"},{"issue":"4","key":"13141_CR12","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1124\/pharmrev.124.001073","volume":"76","author":"G Bsteh","year":"2024","unstructured":"Bsteh G et al (2024) Novel and emerging treatments to target pathophysiological mechanisms in various phenotypes of multiple sclerosis. Pharmacol Rev 76(4):564\u2013578","journal-title":"Pharmacol Rev"},{"issue":"11","key":"13141_CR13","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S1474-4422(24)00328-4","volume":"23","author":"X Montalban","year":"2024","unstructured":"Montalban X et al (2024) Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol 23(11):1119\u20131132","journal-title":"Lancet Neurol"},{"key":"13141_CR14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415985","author":"J Oh","year":"2025","unstructured":"Oh J et al (2025) Tolebrutinib versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2415985","journal-title":"N Engl J Med"},{"key":"13141_CR15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415988","author":"RJ Fox","year":"2025","unstructured":"Fox RJ et al (2025) Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2415988","journal-title":"N Engl J Med"},{"issue":"5","key":"13141_CR16","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s10072-023-07228-3","volume":"45","author":"ED Schilke","year":"2024","unstructured":"Schilke ED et al (2024) Current use of fluid biomarkers as outcome measures in multiple sclerosis (MS): a review of ongoing pharmacological clinical trials. Neurol Sci 45(5):1931\u20131944","journal-title":"Neurol Sci"},{"issue":"5","key":"13141_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/14737175.2022.2064743","volume":"22","author":"M Margoni","year":"2022","unstructured":"Margoni M et al (2022) Pediatric multiple sclerosis: developments in timely diagnosis and prognostication. Expert Rev Neurother 22(5):393\u2013403","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"13141_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp-2022-330343","volume":"94","author":"M Margoni","year":"2023","unstructured":"Margoni M et al (2023) Choroid plexus enlargement in paediatric multiple sclerosis: clinical relevance and effect of sex. J Neurol Neurosurg Psychiatry 94(3):181\u2013188","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13141-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13141-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13141-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T13:25:12Z","timestamp":1749907512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13141-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["13141"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13141-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests in relation to this work. Potential conflicts of interest outside the submitted work are as follows: M. Filippi is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology, received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi, speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA, participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda, scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme, he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. P. Preziosa received speaker honoraria from Roche, Biogen, Novartis, Merck, Bristol Myers Squibb, Genzyme, Horizon and Sanofi, he has received research support from Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla. M.A. Rocca received consulting fees from Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche; and speaker honoraria from AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. She receives research support from the MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. She is Associate Editor for Multiple Sclerosis and Related Disorders; and Associate Co-Editor for Europe and Africa for Multiple Sclerosis Journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"385"}}